

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

GRANT OF SHARE OPTIONS

GRANT OF SHARE OPTIONS

The Board of Directors had resolved to grant Share Options to the Grantees to subscribe for up to a total of 16,000,000 Shares, subject to acceptance of the Grantees, under the Share Option Scheme.

This announcement is made pursuant to Rule 17.06A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board (the “**Board**”) of directors (the “**Directors**”) of Fusen Pharmaceutical Company Limited (the “**Company**”) announces that the Company granted 16,000,000 share options (the “**Share Options**”) to eligible grantees (the “**Grantees**”) under the share option scheme of the Company adopted on 14 June 2018, subject to the acceptance of the Grantees, details of which are set out below:

Date of grant:	19 July 2019 (the “ Date of Grant ”)
Exercise price of the Share Options:	HK\$3.098 to subscribe for one ordinary share of HK\$0.01 each in the share capital of the Company (the “ Share ”), which is higher than the highest of (i) the closing price of HK\$3.04 per Share as stated in the daily quotations sheets issued by The Stock Exchange of Hong Kong Limited (the “ Stock Exchange ”) on the Date of Grant; (ii) the average closing price of HK\$3.098 per Share as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant; and (iii) the nominal value of HK\$0.01 per Share
Number of Share Options granted:	16,000,000 Share Options (each Share Option shall entitle its holder to subscribe for one Share)

Validity period of the Share Options: from 19 October 2019 to 19 July 2020

Vesting date of the Share Options: 19 October 2019

The Company confirms none of the Grantees is a Director, chief executive or a substantial shareholder (as defined in the Listing Rules) of the Company, or an associate (as defined in the Listing Rules) of any of them.

By Order of the Board
Fusen Pharmaceutical Company Limited
Cao Changcheng
Chairman and Executive Director

Hong Kong, 19 July 2019

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Dudu as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Mr. Ho Ka Chun as independent non-executive Directors.